Loomis, Sayles & Company
AMAG

Loomis, Sayles & Company’s AMAG Pharmaceuticals AMAG Stock Holding History

Loomis, Sayles & Company’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-152
Closed -$3K – 978
2017
Q3 		$3K Hold
152
– – ﹤0.01% 882
2017
Q2 		$3K Hold
152
– – ﹤0.01% 902
2017
Q1 		$3K Sell
152
-190
-56% -$4.55K ﹤0.01% 919
2016
Q4 		$12K Buy
342
+152
+80% +$4.54K ﹤0.01% 827
2016
Q3 		$5K Hold
190
– – ﹤0.01% 892
2016
Q2 		$5K Buy
190
+101
+113% +$2.32K ﹤0.01% 863
2016
Q1 		$2K Buy
+89
New +$2.11K ﹤0.01% 1001

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company's AMAG Position: Q4 2017 in Review

Loomis, Sayles & Company sold out of AMAG Pharmaceuticals (AMAG) in Q4 2017, closing a stake of 152 shares — an estimated $3K sold.

Loomis, Sayles & Company first reported a position in AMAG in Q1 2016 and held it in 7 quarters. The position peaked at $12K in Q4 2016. 170 funds tracked by Wall St. Rank hold AMAG as of Q4 2017.

  • Loomis, Sayles & Company reported no remaining AMAG Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Loomis, Sayles & Company sold 152 AMAG Pharmaceuticals shares in Q4 2017, an estimated $3K.
  • Loomis, Sayles & Company first reported a position in AMAG Pharmaceuticals in Q1 2016 and held it in 7 quarters.
  • Loomis, Sayles & Company's AMAG Pharmaceuticals position peaked at $12K in Q4 2016.
  • 170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2017.

Based on Loomis, Sayles & Company's 13F filing for Q4 2017, filed 14 Feb 2018.